前沿生物牵手GSK交易额超10亿美元 聚焦小核酸创新药扣非连续三年减亏

Core Viewpoint - Frontier Biotech has entered into a significant international collaboration with GlaxoSmithKline (GSK), granting GSK exclusive global rights to develop, manufacture, and commercialize two small RNA (siRNA) drug candidates, with a total transaction value potentially exceeding $1 billion [1][2]. Group 1: Collaboration Details - The agreement includes an upfront payment of $40 million and a milestone payment of $13 million, with potential additional milestone payments of up to $950 million based on development, regulatory, and commercialization achievements [2][3]. - The two siRNA products are in early development stages, with one candidate having entered the Investigational New Drug (IND) application phase and the other in preclinical development, both targeting inflammation-driven diseases such as kidney diseases [2][3]. Group 2: Financial Implications - The collaboration is expected to significantly improve Frontier Biotech's cash flow, providing funding for core pipeline development and technology platform upgrades, while allowing the company to focus its research resources and optimize its financial structure [3]. - For 2025, Frontier Biotech forecasts a revenue of approximately CNY 140 million to CNY 145 million, representing a year-on-year growth of 8.13% to 11.99%, while the net loss attributable to shareholders is projected to be between CNY 255 million and CNY 290 million [6]. Group 3: R&D Focus and Strategy - Frontier Biotech is undergoing its third transformation, shifting towards a dual-driven model of "innovative drugs + high-end generics," with a strong emphasis on small RNA drug development [6]. - The company has achieved a reduction in net profit losses for three consecutive years, with the expected loss for 2025 being between CNY 288 million and CNY 323 million, a decrease of CNY 4.31 million to CNY 39.31 million compared to the previous year [6].